Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
1.150
+0.020 (1.77%)
At close: Dec 9, 2025, 4:00 PM EST
1.140
-0.010 (-0.87%)
After-hours: Dec 9, 2025, 7:49 PM EST
Phio Pharmaceuticals Employees
Phio Pharmaceuticals had 5 employees as of December 31, 2024. The number of employees decreased by 4 or -44.44% compared to the previous year.
Employees
5
Change (1Y)
-4
Growth (1Y)
-44.44%
Revenue / Employee
n/a
Profits / Employee
-$1,590,600
Market Cap
12.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | -4 | -44.44% |
| Dec 31, 2023 | 9 | -1 | -10.00% |
| Dec 31, 2022 | 10 | -2 | -16.67% |
| Dec 31, 2021 | 12 | 2 | 20.00% |
| Dec 31, 2020 | 10 | -1 | -9.09% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PHIO News
- 14 days ago - Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 - Newsfile Corp
- 22 days ago - Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress - Newsfile Corp
- 26 days ago - Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial - Newsfile Corp
- 5 weeks ago - Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director - Newsfile Corp